Citizens reiterates Allogene stock rating on pipeline progress
#Allogene #Citizens #stock rating #pipeline #biotech #investment #clinical trials
📌 Key Takeaways
- Citizens maintains its stock rating for Allogene Therapeutics.
- The decision is based on progress in Allogene's drug pipeline.
- Allogene is advancing its clinical development programs.
- The rating reflects confidence in the company's future prospects.
🏷️ Themes
Biotechnology, Finance
Entity Intersection Graph
No entity connections available yet for this article.